Sandra Chan, Joanna Tsai, Elizabeth Xiao Wang, Aug 26, 2013
Merger remedies imposed by China’s merger review agency, Ministry of Commerce (“MOFCOM”), have received considerable attention in the antitrust community. Understanding and being prepared for the unique aspects of merger remedies imposed by MOFCOM can be crucial to developing a successful global M&A strategy.
When a merger is determined to have anticompetitive effects, competition agencies may choose to approve the merger contingent upon conditions imposed on the transaction to preserve competition rather than blocking the transaction entirely. These conditions are one form of merger remedy. In general, merger remedies can be classified into two broad categories: structural remedies and behavioral remedies. Structural remedies are aimed at preserving competition by requiring the merged firm to divest certain assets, whether physical or intangible, to a new or existing competitor, to ensure that the competitor possesses both the “means and the incentive to effectively preserve competition.” Behavioral remedies, as the name suggests, regulate certain future behaviors of the merged firm. A hybrid approach consisting of a combination of structural and behavioral remedies may also be used to prevent harm to competition.
Since the enactment of China’s Anti-monopoly Law in August 2008, MOFCOM has reviewed more than 600 proposed mergers and acquisitions. MOFCOM approved 97 percent of
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.194
Please verify email or join us
to access premium content!
